Abstract:Purpose: This article summarizes data submitted to the United States Food and Drug Administration for marketing approval of zoledronic acid (Zol; Novartis Pharmaceuticals, East Hanover, NJ), a bisphosphonate drug for treating patients with bone metastases. Experimental Design: We review the chemistry, toxicology, pharmacology, and clinical study results submitted to support the supplemental New Drug Application for Zol for treatment of patients with bone metastases. Four- and 8-mg Zol doses were selected for Phase III trials based on bone resorption markers and clinical efficacy parameters. Patients with bone metastases were randomized in three Phase III studies (prostate cancer, solid tumors, and multiple myeloma or breast cancer) to receive 4 or 8 mg of Zol or to a control arm. The control was a placebo in the prostate cancer study and the other solid tumor study and was 90 mg of pamidronate (Pam) in the study of breast cancer and multiple myeloma. Studies were amended twice because of renal toxicity, initially to increase Zol infusion time from 5 to 15 min and later to decrease the dose in the Zol 8-mg arm to 4 mg. The efficacy end point was skeletal-related events (SREs), a composite end point consisting of pathologic fracture, radiation therapy to bone, changes in antineoplastic therapy for bone pain (prostate cancer only), surgery to bone, or spinal cord compression. This end point was analyzed either as the proportion of patients with SRE or time to first SRE. The breast cancer and myeloma study used a noninferiority statistical analysis methods to determine efficacy. Results: In prostate cancer, both the proportions analysis and time-to-SRE analysis showed significantly less bone morbidity on Zol (4 mg) than placebo, but no significant difference between Zol (8 mg) and placebo in either analysis. In the solid tumor study, the time to SRE analysis but not the proportions analysis showed significantly less skeletal morbidity on Zol (4 mg) than placebo, and Zol (8 mg) was significantly better than placebo in both analyses. The breast cancer and myeloma study demonstrated noninferiority of Zol compared with Pam, with Zol retaining at least 49.3% of the Pam treatment effect previously demonstrated in placebo-controlled trials. Zol was approved on February 22, 2002, by the United States Food and Drug Administration for the “treatment of patients with multiple myeloma and documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.” The recommended dose and schedule is 4 mg of Zol infused over 15 min every 3– 4 weeks. Increased Zol doses and shorter infusions are not recommended because of potential renal toxicity.

Zoledronic Acid Overcomes Adriamycin Resistance in Acute Myeloid Leukemia Cells by Promoting Apoptosis

Zoledronic acid inhibits proliferation and induces apoptosis in U937 cells

Zoledronate Attenuates Angiogenic Effects Of Angiotensin Ii-Stimulated Endothelial Progenitor Cells Via Rhoa And Mapk Signaling

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Zoledronic acid exerts antitumor effects in NB4 acute promyelocytic leukemia cells by inducing apoptosis and S phase arrest.

Zoledronate Can Promote Apoptosis and Inhibit the Proliferation of Colorectal Cancer Cells

Research Progress on Antitumor Effects of Zoledronic Acid

Zoledronic Acid Augments the Radiosensitivity of Cancer Cells Through Perturbing S- and M-phase Cyclins and P21cip1 Expression.

Inhibition of Bcl-xL Overcomes Polyploidy Resistance and Leads to Apoptotic Cell Death in Acute Myeloid Leukemia Cells

In vitro and in vivo evaluation of cationic liposomes containing zoledronic acid as anticancer agent

Induced Effect of Zinc oxide nanoparticles on human acute myeloid leukemia cell apoptosis by regulating mitochondrial division

New Insights into the Actions of Bisphosphonate Zoledronic Acid in Breast Cancer Cells by Dual RhoA-dependent and -Independent Effects

APG-1252-12A Induces Mitochondria-Dependent Apoptosis Through Inhibiting the Antiapoptotic Proteins Bcl-2/Bcl-xl in HL-60 Cells

Zoledronic Acid Inhibits Osteoclast Differentiation And Function Through The Regulation Of Nf-Kappa B And Jnk Signalling Pathways

Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia

Report from the FDA Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review

Antiproliferative Effect of ZSTK474 Alone or in Combination with Chemotherapeutic Drugs on HL60 and HL60/ADR Cells

Zoledronic Acid Inhibits Osteoclastogenesis and Bone Resorptive Function by Suppressing RANKL‑mediated NF‑κB and JNK and Their Downstream Signalling Pathways.

Integrated stress response activation induced by usnic acid alleviates BCL-2 inhibitor ABT-199 resistance in acute myeloid leukemia

CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.